ArticleScientific reports2025
Prognostic value of systemic inflammation markers in early stage non-small cell lung cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Baseline Neutrophil-to-Lymphocyte Ratio and Two-Year Incident Distant Metastasis in Stage I-III Lung Cancer: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Prognostic impact of preoperative immunenutritional indices in patients undergoing curative resection for non-small cell lung cancer: a retrospective analysis.Journal of thoracic disease · 2026Article
- Prognostic value of perioperative inflammatory biomarkers in patients undergoing surgical resection for non-small cell lung cancer.Journal of thoracic disease · 2026Article
- The predictive value of systemic inflammation response index and albumin-to-globulin ratio for prognosis in non-small cell lung cancer.Scientific reports · 2026Article
- Mean Corpuscular Volume as a Prognostic Marker in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection: A Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- The Prognostic Role of Different Blood Cell Count-to-Lymphocyte Ratios in Patients with Lung Cancer at Diagnosis.Cancers · 2025Article
- A Prognostic Nomogram Combining Postoperative SII and PIV Improves Long-Term Survival Prediction in NSCLC.Journal of inflammation research · 2025Article
- An Emergency-deployable Albumin-enhanced NLR Derived by Machine Learning Improves Risk Stratification in Lung Cancer: A Multicenter Cohort Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigates the prognostic significance of systemic inflammation markers in patients with early-stage non-small cell lung cancer (NSCLC), who underwent surgical treatment. We retrospectively analyzed data from 2,159 patients, who underwent lung resection for stage I-IIA NSCLC in nine centers between the years 2010 and 2022. In order to compare survival, we grouped the patients by preoperative neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and pan-immune inflammation value (PIV). The mean overall survival (OS) was significantly shorter in patients with high NLR (102.7 vs. 109.4 months, p = 0.040). A low LMR was associated with worse OS (101 vs. 110.3 months, p < 0.001) and worse disease-free survival (DFS) (100.2 vs. 108.6 months, p = 0.020). A high PLR was a poor prognostic factor for both OS (104.1 vs. 110.1 months, p = 0.017) and DFS (102.5 vs. 108.7 months, p = 0.021). A high PIV was associated with worse DFS (101.2 vs. 109.8 months, p = 0.003). Patients with high PIV had longer time to chest tube removal (6.9 vs. 6.7 days, p = 0.049) and longer hospital stays (8.6 vs. 8.2 days, p < 0.001). Complication rates were higher in patients with lower LMR (33.8% vs. 29.4%, p = 0.028) and higher PLR (38.1% vs. 33.1%, p = 0.016). In our multicenter study, OS was worse in patients with high PLR, high NLR, and low LMR. DFS was worse in patients with high PIV, high PLR, and low LMR. NLR, LMR, PLR, and PIV were associated with OS and DFS in early-stage NSCLC, but none of the circulating inflammatory markers proved to be statistically significant in the multivariate analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.